SEC Company Response from Outlook Therapeutics, (OTLK) — Apr 9, 2019
Outlook Therapeutics, Inc.
Date: April 9, 2019 · CIK: 0001649989 · Accession: 0001144204-19-018750
AI Filing Summary & Sentiment
File numbers found in text: 333-229761
Letter
Lawrence A. Kenyon
President, CEO and CFO
7 Clarke Drive
Cranbury, NJ 08512
April 9, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jeff Gabor
Re: Outlook Therapeutics, Inc.
Registration Statement on Form S-1
File No. 333-229761
Acceleration Request
Requested Date: Tuesday, April 9, 2019
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 (File No. 333-229761) (the “Registration Statement”) to become effective on Tuesday, April 9, 2019, at 5:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its outside counsel, Cooley LLP, may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been declared effective, please orally confirm that event with Marianne Sarrazin of Cooley LLP at (415) 693-2157 or Pia Kaur of Cooley LLP, at (415) 693-2135.
Very truly yours,
Outlook Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Lawrence A. Kenyon
President, CEO and CFO
7 Clarke Drive
Cranbury, NJ 08512
April 9, 2019
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Mr. Jeff Gabor
Re: Outlook Therapeutics, Inc.
Registration
Statement on Form S-1
File No. 333-229761
Acceleration Request
Requested Date: Tuesday, April 9, 2019
Requested Time: 5:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities
and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration
Statement on Form S-1 (File No. 333-229761) (the “Registration Statement”) to become effective on Tuesday,
April 9, 2019, at 5:00 p.m. Eastern Time, or as soon thereafter as is practicable, or at such later time as the Registrant or its
outside counsel, Cooley LLP, may orally request via telephone call to the staff (the “Staff”).
Once the Registration Statement has been
declared effective, please orally confirm that event with Marianne Sarrazin of Cooley LLP at (415) 693-2157 or Pia Kaur of Cooley
LLP, at (415) 693-2135.
Very truly yours,
Outlook Therapeutics, Inc.
By:
/s/ Lawrence
A. Kenyon
Lawrence A. Kenyon
President, Chief Executive Officer and
Chief Financial Officer
cc: Yvan-Claude Pierre, Cooley LLP
Marianne
Sarrazin, Cooley LLP
Pia Kaur, Cooley LLP
T: 609.619.3990 | W: www.outlooktherapeutics.com | E:
info@outlooktherapeutics.com